Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.69), $0.02 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $26.7 million versus the consensus estimate of $25.8 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.